Carey Olsen Advises Inflexion on £2.3 Billion Continuation Fund
Funding | 20 May 2025 | Carey Olsen
Inflexion, a private equity firm, has secured a £2.3 billion continuation fund with advisory support from Carey Olsen. This new fund aims to back Inflexion portfolio companies such as Aspen Pumps, Rosemont Pharmaceuticals, Ocorian, and CNX Therapeutics, enhancing their growth trajectories, particularly in the mergers and acquisitions sphere. Through this transaction, existing investors in Inflexion will receive net proceeds of £1.5 billion, achieving a realised return multiple of 3.4x and an internal rate of return (IRR) of 28%, while also having the chance to reinvest. Since its inception in 1999, Inflexion has completed 71 exits with an average IRR of 33%. Carey Olsen's Guernsey corporate team played a pivotal role in facilitating this endeavour, highlighting a long-standing partnership integrated into the strategic goals of organic growth, international expansion, and M&A. Carey Olsen has a history of advising Inflexion on successful fundraisers, including the final close of Enterprise Fund VI and other notable funds.
Sectors
- Private Equity
- Professional Services
Geography
- United Kingdom – Inflexion is a UK-based private equity firm involved in the transaction.
- Guernsey – Carey Olsen's advisory team is based in Guernsey and is integral in facilitating this financial transaction.
Industry
- Private Equity – Inflexion's establishment and management of a £2.3 billion continuation fund is a significant private equity transaction.
- Professional Services – Carey Olsen, as a legal advisor, plays a crucial role in strategically advising Inflexion on this transaction.
Financials
- £2.3 billion – The size of the new continuation fund secured by Inflexion.
- £1.5 billion – Net proceeds received by existing Inflexion investors from the transaction.
- 3.4x – Realised return multiple achieved for Inflexion investors.
- 28% – Internal Rate of Return (IRR) achieved from the transaction.
- 33% – Average IRR achieved by Inflexion from its 71 exits since 1999.
- Enterprise Fund VI at 975 million, Collective 1 billion Close – Previous fund closures advised by Carey Olsen for Inflexion.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Inflexion | Private Equity Firm | Company | A private equity firm focused on backing portfolio companies through strategic funds. |
| Carey Olsen | Legal Advisor | Company | A legal advisory firm providing services in corporate and financial sectors. |
| Aspen Pumps | Portfolio Company | Company | One of the portfolio companies that will benefit from the continuation fund. |
| Rosemont Pharmaceuticals | Portfolio Company | Company | Pharmaceutical company part of Inflexion's portfolio targeted for growth. |
| Ocorian | Portfolio Company | Company | A financial services provider in Inflexion's portfolio targeted by the fund. |
| CNX Therapeutics | Portfolio Company | Company | A healthcare company included in the Inflexion portfolio set for growth. |
| Andrew Boyce | Partner | Person | Partner at Carey Olsen involved in advising on the transaction. |
| Rachel de la Haye | Partner | Person | Partner at Carey Olsen advising on the deal. |
| Oliver Orton | Senior Associate | Person | Senior Associate at Carey Olsen involved in the transaction. |
| Nicola D'Amico | Associate | Person | Associate at Carey Olsen working on the deal. |